For the quarter ended March 2024, Halozyme Therapeutics (HALO) reported revenue of $195.88 million, up 20.8% over the same period last year. EPS came in at $0.79, compared to $0.47 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $201.72 million, representing a surprise of -2.90%. The company delivered an EPS surprise of +14.49%, with the consensus EPS estimate being $0.69.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...